Description
TACS•XL®kitsare basedontheincorporationofbromodeoxyuridine(BrdU)atthe3’OHendsoftheDNAfragmentsthatareformedduringapoptosis.TheincorporationofBrdUbyTdTismoreefficientthaneitherbiotinylatedordigoxigeninlabelednucleotidesusedinotherterminaldeoxynucleotidyltransferasedUTPnickendlabeling(TUNEL)-basedassays.Thedetectionsystemutilizesabiotinconjugatedanti-BrdUantibodyandstreptavidin-horserADIshperoxidase.Thecombinationofantibodyspecificitywiththesignalenhancingpropertiesofbiotinstreptavidinresultsinprecisecellularlabelingandthehighestsignal-to-noiseratioobservedincompetitivetesting.
Pleaserefertoourcomponentslistingfordetails.
Catalog#4828-30-Rincludes: | ||
CatalogNumber | Description | Qty |
4800-30-01 | ProteinaseK | 1 |
4800-30-06 | Streptavidin-HRP | 1 |
4810-30-05 | TdTEnzyme | 1 |
4828-30-04 | B-dNTPMix | 1 |
4828-30-06 | anti-BrdUantibody | 1 |
4828-30-12 | Strep-Diluent | 1 |
4876-05-01 | Cytonin™ | 1 |
Trevigen公司位于美国马里兰州的高科技走廊,是一家有12年历史、成长迅速的生物技术公司,其产品和技术的发展方向主要在癌症研究领域,重点强调细胞凋亡、DNA损伤和修复,以及癌症细胞功能和行为。Trevigen品牌的分销商遍及北美,欧洲和环太平洋地区。关于DNA的损伤分析技术的研究,Trevigen获得美国国立卫生研究院(NIH)的SBIR项目资助。